Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Market Update

Julia Lee
June 27, 2017

Market Update

Julia Lee
June 26, 2017

Market Update

Julia Lee
June 23, 2017

YMYC 22 June 2017

Julia Lee
June 22, 2017

Market Update

Julia Lee
June 21, 2017

Market Update

Julia Lee
June 20, 2017

Market Update

Julia Lee
June 19, 2017

Market Update

Julia Lee
June 16, 2017

Market Update

Julia Lee
June 15, 2017

Market Update 14 June

Julia Lee
June 14, 2017

Market Update

Julia Lee
June 13, 2017